Fidelity Investments Variable Annuity Account I has made a significant update to its summary prospectus, which is crucial for investors and the broader investment community. The update, effective November 1, 2026, includes changes in the current expenses for its Fidelity VIP Investor Freedom Portfolios. This move is part of Fidelity's ongoing efforts to enhance transparency and provide investors with the most current information regarding their investments.
The update is particularly important as it reflects Fidelity's commitment to keeping its investors informed about any changes that may impact their investment decisions. By updating the summary prospectus, Fidelity aims to ensure that investors are aware of the costs associated with their variable annuity products, which can influence their investment choices.
Background
Fidelity Investments Variable Annuity Account I is an investment entity incorporated in Utah. It operates under the Central Index Key (CIK) number 0000821051. The company primarily focuses on providing variable annuity products, which are designed to offer investment options and insurance benefits to policyholders. Recent filings include multiple forms, with the most recent being filed on October 30, 2026.
What the Filing Says
The SEC filing states, "Effective November 1, 2026, current expenses for the Fidelity VIP Investor Freedom Portfolios have changed." This update is crucial as it directly impacts the costs associated with these investment options.
Impact
This update may affect current and potential investors in Fidelity's variable annuity products, as well as those considering similar investment options from competitors. By providing updated cost information, Fidelity aims to maintain investor trust and confidence in its offerings.
What's Next
The filing does not say what happens next.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






